BioAge Labs, Inc. (BIOA) stock
BIOANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30
$4.77−0.33 (-6.47%)
Close on Nov 18, 2026Market cap $218.93MP/E –Yield –
BioAge Labs operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
BioAge Labs's operating income for the twelve months ending Jun 30, 2026 was -$106.27M. For fiscal 2025 it was -$92.78M.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$92.78M | – |
| FY2024 | Dec 31, 2024 | -$78.19M | – |
| FY2023 | Dec 31, 2023 | -$48.40M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$29.33M | – |
| Q1 FY2026 | Mar 31, 2026 | -$25.38M | – |
| Q4 FY2025 | Dec 31, 2025 | -$28.42M | – |
| Q3 FY2025 | Sep 30, 2025 | -$23.14M | – |
| Q2 FY2025 | Jun 30, 2025 | -$24.77M | – |
| Q1 FY2025 | Mar 31, 2025 | -$16.45M | – |
| Q4 FY2024 | Dec 31, 2024 | -$25.36M | – |
| Q3 FY2024 | Sep 30, 2024 | -$24.75M | – |
| Q2 FY2024 | Jun 30, 2024 | -$15.27M | – |
| Q1 FY2024 | Mar 31, 2024 | -$12.81M | – |
| Q4 FY2023 | Dec 31, 2023 | -$13.60M | – |
| Q3 FY2023 | Sep 30, 2023 | -$9.89M | – |
See a number that looks wrong?